A Study of Gemcitabine ยฑ Erlotinib and DN-101 Versus Gemcitabine ยฑ Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Novacea
- Target Recruit Count
- 132
- Registration Number
- NCT00536770
- Locations
- ๐บ๐ธ
Novacea Investigational Site, Nashville, Tennessee, United States
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2007-05-30
- Lead Sponsor
- Novacea
- Target Recruit Count
- 60
- Registration Number
- NCT00394628
- Locations
- ๐บ๐ธ
University of California, Los Angeles, Los Angeles, California, United States
๐บ๐ธHenry Ford Health Systems, Detroit, Michigan, United States
๐บ๐ธNorthwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2006-05-31
- Lead Sponsor
- Novacea
- Target Recruit Count
- 25
- Registration Number
- NCT00285675
- Locations
- ๐บ๐ธ
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
๐บ๐ธUniversity of Pittsburgh,William Copper Ambulatory Care, Pavillion Hellman Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธKaiser Permanente Medical Group, Northern California, Vallejo, California, United States
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Novacea
- Target Recruit Count
- 1200
- Registration Number
- NCT00273338
- Locations
- ๐บ๐ธ
UCLA department of Urology, Los Angeles, California, United States
๐บ๐ธHematology Oncology Associates of Illinois, Chicago, Illinois, United States
๐บ๐ธThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Novacea
- Target Recruit Count
- 55
- Registration Number
- NCT00109356
- Locations
- ๐บ๐ธ
Weill Medical College of Cornell University/ New York Presbyterian Hospital, New York, New York, United States
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2006-11-02
- Lead Sponsor
- Novacea
- Target Recruit Count
- 45
- Registration Number
- NCT00090727
- Locations
- ๐บ๐ธ
Weiler Hospital of Albert Einstein College of Medicine, Bronx, New York, United States
๐บ๐ธCancer Therapy & Research Center / Institute for Drug Development, San Antonio, Texas, United States
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-08-08
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Novacea
- Target Recruit Count
- 80
- Registration Number
- NCT00066885
- Locations
- ๐บ๐ธ
New York Oncology Hematology, P.C. - Albany Regional Cancer Center, Albany, New York, United States
๐บ๐ธCancer Care Associates, Tulsa, Oklahoma, United States
๐บ๐ธSwedish Cancer Institute, Seattle, Washington, United States
Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)
- Conditions
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Novacea
- Target Recruit Count
- 46
- Registration Number
- NCT00057031
- Locations
- ๐บ๐ธ
Oregon Health Sciences University, Portland, Oregon, United States
๐บ๐ธBoston Baskin Cancer Group, Memphis, Tennessee, United States
๐บ๐ธJames A. Haley Veterans Hospital, Tampa, Florida, United States
A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
- Conditions
- First Posted Date
- 2003-02-25
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- Novacea
- Target Recruit Count
- 60
- Registration Number
- NCT00055263
- Locations
- ๐บ๐ธ
Oregon Health & Science University, Portland, Oregon, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
- Conditions
- First Posted Date
- 2002-08-13
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Novacea
- Target Recruit Count
- 250
- Registration Number
- NCT00043576
- Locations
- ๐บ๐ธ
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
๐บ๐ธTexas Oncology, P.A., Dallas, Texas, United States
๐บ๐ธKaiser- Northern California, Vallejo, California, United States